Regeneron: Trial COVID-19 drug cocktail cut virus load in more people

/ / News

Shares of Regeneron Pharmaceuticals Inc. rose more than 3% in the extended session Wednesday after the company said its experimental antibody cocktail “significantly reduced” novel-coronavirus levels and the need for “further medical attention,” including hospitalizations and emergency-room visits, in more people enrolled in its ongoing late-stage trial. “We continue to see the strongest effects in patients who are most at risk for poor outcomes due to high viral load, ineffective antibody immune response at baseline, or pre-existing risk factors,” Regeneron’s President and Chief Scientific Officer George D. Yancopoulos said in a statement. Regeneron, which earlier this month said it had submitted a request for emergency authorization to the Food and Drug Administration for the experimental antibody treatment, said it had shared the new information with the FDA. The cocktail was one of the therapies prescribed to President Donald Trump as part of his COVID-19 treatment.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.